Alivus Life

Q1 FY27Pharmaceuticals & Biotechnology

Alivus Life Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹1,348

Market cap₹16.6K Cr

P/E26.7

Published25 Aug 2026

What the Q1 FY27 call signalled

3 of 4 strong

RevenueRank 3

MarginRank 2

CapexYes

Order bookYes

Not discussed on this call: fundraise.

The short version

Alivus Life Sciences expects revenue growth of 10% to 12% in FY '27, with stronger growth skewed towards the second half of the year. Revenue Growth: Alivus is guiding for 10% to 12% revenue growth in FY '27, with growth skewed towards the second half of the year.

From Alivus Life's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 3

Alivus Life Sciences expects revenue growth of 10% to 12% in FY '27, with stronger growth skewed towards the second half of the year.
Non-GPL business is driving strong growth, with a 26.5% year-on-year increase in Q1 FY '27, supported by a robust product pipeline and recent launches.
CDMO business is anticipated to accelerate in H2 FY '27 and beyond as new projects commercialize, contributing to faster growth than the overall business.
The company is working on 7 active CDMO projects and anticipates closing 2 new CDMO contracts in early H2 FY '27.
Pipeline of 28-29 new high-potent API products being commercialized gradually, with significant launches expected from FY '28 onward.
Volume growth in non-GPL business is about 21-22%, with price declines around 1-2%.
Capacity expansions at Dahej and Ankleshwar as well as Solapur (operational by early Q3 FY '27) will support double-digit growth in FY '27 and FY '28.

Profitability & Margins

Revenue Growth: Alivus is guiding for 10% to 12% revenue growth in FY '27, with growth skewed towards the second half of the year.
Margin Outlook: EBITDA margins are expected to be sustained in the 30% to 32% range, with potential upside to 34% contingent on stable conditions.
CDMO Business: Expected to grow faster than the overall business with contributions from 7 active projects; 2 new CDMO contracts anticipated in early H2 FY '27.
R&D Investment: R&D spend expected to stabilize at around 4% of revenue, primarily driving API pipeline growth and supporting margin improvements.
Profitability: PAT margins have improved and are expected to remain strong; margin growth driven by new API launches and operational efficiencies.
Capacity Utilization: Existing facilities and expansions at Ankleshwar and Dahej support double-digit growth; Solapur facility operational by Q3 FY '27 will boost future capacity.
Long-Term Pipeline: Strong launch momentum in high-potent APIs projected to sustain growth and profitability over the next 4-5 years.

See what Alivus Life said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

Capex for Q1 FY '27 was INR85 crores; expected capex for FY '27 is approximately INR540 crores.
Priority capex focus remains on completion of expansions at Dahej (160KL increase) and Ankleshwar (110KL increase), both on track.
Solapur Phase 1 and 1.1 nearing completion, to be operational by Q3 FY '27, with inspections planned within a year post-operation for regulatory approvals.
Solapur expansion (Phase 3) has been delayed by about a year to avoid under-absorption and is planned as a greenfield project.
New R&D center construction at Taloja has begun and is progressing on schedule.
Investment focus on new API launches and improving manufacturing capabilities, especially for regulated markets.
Strategic investments targeted at synergistic acquisitions focusing on pipeline expansion rather than merely facility acquisition.
Overall, capex and strategic investments are calibrated to support double-digit growth while maintaining operational efficiency.

Fundraising & Capital Structure

There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
The company reported being a debt-free entity with strong cash and cash equivalents of INR880 crores as of June 30, 2026.
Cash flow is described as robust, with no issues in receivables and a strong free cash flow generation of INR90 crores in Q1 FY '27.
The company appears to be funding its capex (expected INR540 crores in FY '27) through internal accruals without requiring external debt or equity.
The focus is on operational discipline and steady growth, indicating no immediate need for fundraising via debt or equity.

See what Alivus Life said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Yes

Alivus Life Sciences is actively engaged in about 7 ongoing CDMO projects.
Revenue currently comes from 5 existing projects.
There are new inquiries beyond these 7 projects, indicating a steady flow of potential business.
The CDMO segment is expected to accelerate growth in H2 FY '27 and continue expanding in FY '28 with new projects kicking in.
The company is confident of maintaining steady demand and growth from its existing pipeline and new launches.
The robust product pipeline includes 29 active high-potent API products with a total addressable market of $82 billion.
The Solapur facility is being readied to increase capacity and contribute to order fulfillment once regulatory approvals are completed.
Overall, Alivus expects orderbook growth driven by new launches, lifecycle management, and specialty CDMO projects.

How does Alivus Life rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAlivus Life

Rev 3Mar 2

See where Alivus Life sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

Alivus Life — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹689 Cr, net profit ₹163 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Alivus Life's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Strides Pharma Science Ltd (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Alivus Life Q1 FY27 results?

What is Alivus Life share price analysis?

Alivus Life currently shows a below-average growth signal. The stock trades at a P/E of 26.7 with a market cap of ₹16,585 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alivus Life planning capital expenditure?

Capex for Q1 FY '27 was INR85 crores; expected capex for FY '27 is approximately INR540 crores.

Keep Alivus Life on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.